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Abstract:
Aluminium is known to cross the blood brain barrier and gain entry to the CNS via 
the endogenous iron transport protein transferrin. The extent to which Al-Tfh binding 
and Al-Tfh intra-cellular movement corresponds to that of Fe-Tfh is unknown. 
Characterising these processes may help us to understand the mechanics underlying 
A1 transport and therefore its role in neurodegenerative disorders such as Alzheimer’s 
and dialysis dementia.
pH binding was studied using fractions eluted via biorad size exclusion 
chromatography columns at pH 5.0 and 6 . 8  and using a buffer/mobile phase of 
lOOmM malic acid solution. The fraction yields were analysed using Unicam PYE 
atomic absorption spectroscopy apparatus, P9000 furnace.
All liver microsomal samples showed significant interference to a degree where 
greater than 90% of the aluminium present remained undetected. This interference 
effect was reproduced with the simple matrices KC1 and sucrose but not with malic 
acid. The analysis of aluminium content of the SEC fractions from Al-Tfh samples at 
pH 5.0 and 6 . 8  showed no differences in elution profile- and an early elution of 
aluminium within a fraction volume incompatible with the molecular weights of 
either transferrin or free aluminium.
The results from both GFAAS and SEC indicated that the experimental techniques 
were unsuitable for achieving the objectives. This conflicts with previous work. 
Further experiments to isolate or minimise the source of the GFAAS interference and
SEC early elution are recommended.
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1.0 Introduction:
1.1 Aluminium toxicity
At high levels or with chronic intake aluminium has been shown to be associated with 
toxic effects in man; principally neurotoxicity and neurodegeneration. Patients 
exposed to high levels of aluminium in dialysate fluids develop ‘dialysis neuropathy’ 
also known as ‘dialysis dementia’- a progressive fatal neurological syndrome 
characterised by speech disorder, dementia and convulsions (de Wolff et al., 2002). 
Post mortem examination of the brains of these patients showed aluminium-enriched 
fibrillar material- tangles. The subsequent introduction of measures to minimise the 
aluminium in dialysate fluids has prevented the occurrence of dialysis neuropathy. 
The occurrence of encephalopathy has also been reported in patients with chronic 
renal failure after the ingestion of Al3+ containing antacids (Klaasen, 1996).
Though aluminium can be seen to be associated with dialysis neuropathy, its role in 
the pathogenesis of other diseases is not clear. Aluminium can act as a potent 
neurotoxicant- in vitro administration of aluminium to cultures of neurones or glial 
cells results in accumulation and damage (Exley, 1999; Platen, 2001). Increasing the 
concentration of Al3+ in the brains of sensitive mammalian species such as cats to 
4pg/g from 1 pg/g can induce impaired brain function and neurodegeneration 
(Klaasen, 1996, Corain et ah, 1996). This is a huge increase however considering an 
average mammalian cerebral cortex contains around 0.2pg/g aluminium (DeWolff, et 
a l, 2002). Emphasising this putative link is the presence of aluminium in the 
neurofibrillary tangles and senile plaques of many AD patients. These plaques are not
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the same as the tangles of dialysis dementia and it may be that accumulation of 
aluminium is secondary to nervous system damage. Epidemiological, human- and 
animal studies indicate it is probable that aluminium, though a potent neurotoxicant 
acts as a co-factor rather than a direct causative agent in neurodegenerative disorders 
such as Alzheimer’s (Klaasen, 1996; Guo & Liang, 2001; Suarez-Femandez et a l, 
1999). Interestingly recent research also links high levels of iron in the brain to 
various neurodegenerative disorders including Alzheimer’s disease (Crichton et a l, 
2002).
1.1.1 Aluminium movement and distribution
Following an acute dose, the greatest proportion of aluminium remains in the serum, 
then slowly distributes to other compartments accumulating in the brain and bone and 
liver. In serum aluminium is distributed approximately 85%-15% between high and 
low molecular weight complexes. The high molecular weight complex is the blood 
transport protein transferrin (Sanz-Medel et a l, 2002). The low molecular weight 
complex is predominantly citrate. Within the brain extracellular fluid the situation is 
reversed and the greatest proportion of aluminium is bound to citrate.
Initially the distribution of Al3+ is consistent with blood volume. Most of aluminium 
in serum is complexed with the transferrin molecule: most of the remainder bound to 
citrate, but also some binding to hydroxide and phosphate molecules, some to binding 
to amino acids and some binding to albumin (Harris, 1996; Yokel & McNamara, 
2001). These charged complexes do not diffuse across membranes. However both Al- 
transferrin and Al-citrate are readily distributed into tissues. Aluminium distribution
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and excretion is enhanced by citrate (Berthon, 2002). Both these molecules are 
believed to facilitate the movement of aluminium across the blood brain barrier.
Trivalent ions do not enter cells by pumps or channels- by active or facilitated 
diffusion (Williams, 1999). Iron however is a required element. The uptake and 
movement of Fe3+ is specially facilitated by the transferrin molecule (Tfn) and 
transferrin receptor (TfhR). Iron unlike aluminium may exist in a divalent as well as 
trivalent state (Fe2+ and Fe3+). It is due to the potential of iron as an oxidising agent 
(Fe3+ —> Fe2+) that it is kept controlled within the body and bound to transport 
molecules. In its divalent state (Fe2+) iron can be taken up by the divalent metal ion 
transporter- DMT1 (Crichton et al., 2002; Gruenheid et al., 1999).
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1.2 Transferrin mediated receptor endocytosis
1.2.1 Transferrin
Transferrin is a molecule of 80,000 Da weight consisting of a single polypeptide chain 
of 679 amino acids and a carbohydrate element (<6 %) of 2 N-linked glycan chains. 
The polypeptide chain assumes a bilobular conformation, each lobule containing 2 
domains. An iron binding cleft is formed between the two domains of each lobe 
(Castellano et a l, 1994). The lobes, domains and clefts of transferrin are not identical 
though the two lobes share a 40% sequence homology (Harris & Messori, 2002).
The two iron binding sites, though not identical both have a similar high affinity for 
the Fe3+ ion (Cochrane et a l, 1984). In both sites the ferric ion is bound in a six- 
coordinate binding environment. Two tyrosine, one histidine and one aspartic acid 
amino acid residues provide 4 ligand-binding groups and a bicarbonate ion provides 
the fifth and sixth coordination sites. The bicarbonate ion is essential in the binding of 
Fe3+ to transferrin and no metal-protein binding occurs in the absence of this 
bicarbonate ion, also known as the synergistic anion.
Al3+ and a number of other trivalent metal ions show a high affinity binding to 
transferrin. Differences in the binding of Fe3+ and Al3+ to Tfn exist: aluminium binds 
to transferrin with a lower affinity than Fe3+ and Al3+ shows a slight preference for the 
N-lobe of Tfn (Berthon, 2002; Nagaoko & Maitani, 2001).
On the binding of iron to transferrin the two domains rotate towards each other by 
approximately 60 degrees giving a closed conformation (see figure 1). This structural
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change is important in receptor binding and for the receptor binding regulation. Low 
pH produces conformational change and causes the Tfn molecule to assume the open 
configuration and release the metal ion. The open configuration in which neither of 
the two binding sites is occupied is known as apotransferrin (see figure 1). At neutral 
pH apotransferrin has little affinity for the transferrin receptor- having a conformation 
which does not readily bind to the receptor.
Figure 1 : Representation of the molecular configurations of transferrin and 
apotransferrin. From: Harris, W. (2002). Binding and transport of aluminium by 
serum proteins. Coordination Chemistry Reviews: 228, 237-262.
In vivo transferrin is particularly important as a serum transport protein- necessary for 
transportation of iron from the liver, its main site of storage and the intestine, the site 
of iron absorption to all cells and tissues. Transferrin is ubiquitous and necessary in 
almost all tissues; this is illustrated in that a key component in the medium of serum 
free cell cultures is transferrin. An abundance of Tfn is available for the transport of 
AF+ ions due to the fact that in normal conditions up to two thirds of the total binding 
capacity of Tfn remains unutilised by Fe3+ ions. Total serum concentration of
/
Ferric N -L obc C om plex N Lobe Apoprotein
URN: 3254305 5
transferrin is around 35{j.M, the binding capacity double this (due to two molecular 
binding sites). The remaining binding capacity of serum transferrin of up to 50pM is 
more than enough to preclude competition between aluminium and iron for transferrin 
binding sites. The highest serum levels of aluminium now seen in patients are up to 
5pM. After binding the movement of transferrin and metal into cells is facilitated by 
binding to the transferrin receptor and receptor-mediated endocytosis.
1.2.2 Transferrin receptors
The transferrin receptor (TfhR) consists of two polypeptide subunits each of a 
molecular weight of 95,000 Da (see figure 2).
Iron Transferrin Transferrin Binding Site
COOH COOHMr x 10*3
) N-linked gtycans 
O Asn 727
If 104
O-linked glycan
70
•"O  Asn 317
Site of 
Trypsin Cleavage
Asn 251
Covalently j 
20  Bound— 5 
I Fatty Acid J
Plasma
Membrane
Figure 2: Diagrammatic representation of the transferrin receptor. From: Ponka, P., 
Lok, C.N. (1999). The transferrin receptor: role in health and disease. The 
International Journal o f  Biochemistry & Cell Biology: 31, 1111-1137.
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The transferrin receptor is present in the plasma membrane of all human and animal 
cells and is particularly abundant in rapidly proliferating cells or cells with a high iron 
requirement. Two subsets exist TfhRl and TfiiR2. Hepatocytes express high levels of 
TfhR (Berthon, 2002). TfhRl is expressed in all cells but liver cells also express 
TfhR2. TfhRl receptors are subject to downregulation by levels of ferritin whereas 
TfhR2 are not (Trin-der & Baker, 2003).
1.2.3 Receptor mediated endocytosis and recycling
Once bound to the transferrin receptor, the transfemn-ligand and receptor complex 
enter the cell by receptor-mediated endocytosis (see figure 3). The bound receptor is 
taken into the cell by an invagination of the membrane and a budding off process, 
which forms an internalised vesicle or endosome (see figure 3, step 2). Clathrin 
molecules coat the forming vesicle and provide a shape but are shed as the fully 
internalised vesicle moves into a cell. The internalised receptor vesicle moves to and 
merges with an early endosome. The ligand is released from the Tfn in the early 
endosome. It is believed that most of the Tfii-TfiiR is recycled back to the cell surface 
from the early endosome. However a fraction of the receptor and bound apo­
transferrin may move to the late endosome, where it will also be recycled to the 
luminal surface (Jackie et al., 1991). Each of these endosome types (receptor, early 
and late) is distinct: functionally, geographically and biochemically (protein 
composition of membrane) (Alberts et a l, 2001, Scheff et al., 1999). The early 
endosome is involved in sorting and targeting. The late endosome is involved in 
sorting. The late endosome is located towards the perinuclear (centre) area of the cell.
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Figure 3: Schematic representation of the sequence of events in receptor mediated 
endocytosis of transferrin and transferrin receptor. From: Ponka, P., Lok, C.N. (1999). 
The transferrin receptor: role in health and disease. The International Journal o f  
Biochemistry & Cell Biology’. 31, 1111-1137.
1.2.4 Release of ligands from transferrin
The early endosome has a low pH of around 5.5 maintained by H+ pumps present in 
the endosome membrane (see figure 3, step 3). The Cl" pumps also present have the 
effect of avoiding creation of an electron gradient. Low pH causes transferrin to 
release ligand but at the same time the low pH causes apotransferrin to retain affinity 
for- and remain bound to- the receptor. The Tfn receptor aids the conformational 
change and ligand release (Ponka & Lok, 1999; & Quian & Tang, 1995). With the 
recycling of receptor and apotransferrin to the plasma membrane where a neutral pH 
environment exists, the apotransferrin is released into the extracellular environment 
(see figure 3, step 5).
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In the early endosome free Fe3+ ions are enzymatically reduced to Fe2+ and these ions 
released into the cell (see figure 3, step 4). It is believed that Fe2+ migrates out of the 
cell through divalent metal ion transporter (DMT1) present in the endosome 
membrane (Crichton et a l, 2002). It is unclear whether the binding characteristics of 
Al3+ at low pH match that of iron. Al3+ cannot be reduced to a divalent cation and 
cannot exit endosomes using DMT1.
1.2.5 Receptor transcytosis
In hepatocytes and epithelial cells apotransferrin has been shown to be released at 
surfaces other than the luminal/apical surface. The only explanation for this 
occurrence is the translocation of some receptor-transferrin to the basolateral surfaces- 
movement across the cell or transcytosis. Other cells though do not have such 
delineated surfaces as epithelial or hepatocytes but have comparable luminal and non- 
luminal faces. It is believed that transcytosis may account for the movement of 
transferrin and A13+ ions across endothelial cells of the BBB (van Gelder et ah, 1997; 
Yokel et ah, 1999).
1.3 Study Design
1.3.1 Method validation
Validation of analytical methods is the measurement of key parameters of 
performance such as accuracy, precision, specificity, linearity and range, limits of 
detection and quantification, intralaboratory variations and interlaboratory variations. 
Method validation should enable us to realise the probabilities of error within a result 
or set of results. Validation of methods is particularly important when using new
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methods or techniques and when deviating from an approved protocol. Method 
validation is essential for this project, though previous work provides a basis and 
reference.
Analytical specificity is the freedom from interference by any element or compound 
in the analyte. Aluminium is known to be susceptible to matrix interference and 
contamination. Contamination may come from many sources including everyday 
items that incorporate aluminium and interference by reagents as well as the matrix. 
Matrix interference will necessitate the formulation of a calibration graph. 
Unavoidable excessive or continuous contamination will necessitate the calculation of 
a contamination rate.
Demonstrating linearity will verify that a sample aluminium content is linearly 
proportional to sample concentration within a given range (statistically measurable by 
the correlation co-efficient or R-squared). Standards additions will be used to 
demonstrate linearity. The range should correspond to the concentrations expected in 
the test sample. A wider range will provide a more confident linearity: that the 
standards are well removed from nonlinear response concentrations. Increasing the 
number standards will allow the detection of possible curvature.
Calculating the limit of detection will enable us to put a figure on the level of 
instrumental variation or ‘noise’ expected within a working run- allowing 
quantification of uncertainty. The limit of detection is equivalent to three times the 
standard deviation (±3 s.d.). The limit of quantification is a figure equivalent to the 
threshold which accuracy/precision may be determined (±10 s.d.). The limit of
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detection will be calculated using the test results from a set of reagent only samples 
(with neither microsomes or aluminium).
Accuracy is the closeness of a measured value to a true value and will be ascertained 
by measuring aluminium content of standard additions- and controls of known 
concentrations. Precision relates to the degree of agreement between measurements of 
a homogenous sample in the same conditions. Multiple testing of a single sample or 
testing of a series of samples identical in composition allows determination of 
precision. Precision also covers the concept of ruggedness. Ruggedness refers to 
variation in results from different analysts, different days or different instruments and 
reproducibility a term to describe interlaboratory variation.
Robustness is the ability to remain unaffected by changing testing parameters such as 
sample storage, sample preparation, and chromatographic conditions. High SEC 
column temperature may cause disintegration of Al-malate species (Busch & Seubert, 
1999) and the storage conditions of Al-organic samples may affect the sample 
integrity (Wilhelm & Ohnesorge, 1990). However these are very likely to prove very 
peripheral factors when compared to the potential difficulties posed by interference 
and contamination (Taylor & Walker, 1992).
Laboratories routinely undertake serum aluminium measurement for the purposes of 
monitoring blood dialysis patients. There are no legal requirements relating to the 
measurement of aluminium in serum. In the UK TEQAS provides performance limits 
for accuracy to within ±17% at lOOjng/1 and 200pg/l (Taylor et a l, 2002). Specialist 
laboratories such as the NHS trace metals analysis laboratory in which we conduct
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our analysis maintain monitoring standards within ±10%. However results falling 
outside ±25% of the target are not uncommon.
Clinical and industrial method validation involves attaining high standards. Though 
we will aim for the high standard of the NHS laboratory, many factors exist which 
will decrease our performance expectation compared to that of the NHS/SAS 
laboratory. These include human error, contamination of samples, inhomogeneity of 
the sample tissues, complexity of the matrices and interference from reagents (Taylor 
et a l, 2 0 0 2 ).
1.3.2 Liver as the test tissue
Studying the endocytosis and transcytosis using BBB tissue would prove difficult. 
Hepatocytes provide a good and proven cell type for studying transferrin transcytosis. 
Transcytosis is expected to occur between cells of liver as iron storage occurs in these 
cells. High expression of transferrin occurs in these cells. In addition hepatocyte 
TfiiR2 content means downregulation would cause less decrease in available Tfii in 
cell culture experiments. In hepatocytes the greatest concentration of TfhR will be 
found on the apical surface.
1.3.2 Techniques for aluminium measurement in biological samples
There are a number of techniques which exist for measurement of aluminium in 
biological samples including: accelerated mass spectrometry, inductively coupled 
mass spectrometry (ICP-MS), inductively coupled atomic emission spectroscopy 
(ICP-AES) and graphite furnace atomic absorption spectroscopy (GFAAS)- also 
known as electrothermal atomic absorption spectroscopy. The most attractive
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technique is accelerated mass spectrometry. AMS is a relatively new technique that 
can be used to accurately measure aluminium in tiny amount of biological materials 
and has a limit of detection of pg/1 (Flarend & Elmore 1997; ATSDR, 1999). Though 
AMS is an ideal choice, the expense and lack of availability in the UK makes it an 
unlikely alternative to GFAAS.
GFAAS is the most commonly used technique for its combination of sensitivity, 
simplicity and lack of expense. The limit of detection for GFAAS is reported at 
around 2 .0 pg/l for whole blood and 0.5pg/g dry weight for liver and similar tissues 
(Bouman et a l,  1986; ATSDR, 1999). The baseline levels of Al3+ in liver from past 
papers are reported variously as: 2.5pg/g human liver dry weight (de Wolff et a l, 
2002, Hongve et a l,  1996), 1.0±0.5pg/g rat liver dry weight (Wilhelm et a l, 1996).
0.2pg/g rat liver wet weight (Gregor & Radnowski, 1995), 12.5pg/g rat liver protein 
(Ward & Crichton, 2001). The wet weight of liver is approximately 5 times that of the 
dry weight. Baseline levels of aluminium are expected to vary.
1.4 Initial experimental objectives
The aims of the project are to elucidate mechanisms by which Al3+ crosses endothelial 
cells of the BBB. We know more about Fe-Tfh movement and uptake than Al-Tfh.
We know many similarities exist but also expect some differences. Both differences 
and similarities may be crucial in determining characteristics of aluminium uptake 
and movement. By understanding the characteristics of Aluminium uptake and 
movement it may be possible to elucidate mechanisms of Al3+ BBB translocation. The 
project objectives could be summarised as:
URN: 3254305 13
I. Method validation.
II. To determine whether the pH dependence binding of aluminium to transferrin 
is the same as that of iron-transferrin. This section will utilise SEC and 
GFAAS.
III. To investigate the binding of Al-Tfh to transferrin receptors in hepatocytes 
and subsequent uptake and movement of Al-Tfh within the endosomal system. 
This will utilise liver homogenate, ultracentrifugation and GFAAS.
IV. On the basis of the viability of experimental techniques and results then the 
subsequent aim will be to examine the endocytotic movement of Al-Tfh using 
in vivo techniques, and to examine the uptake of aluminium-transferrin using 
cultured brain cells.
As the project progressed objectives 3 and 4 were not considered possible within the 
project resource allocation and emphasis shifted to objectives 1 and 2 .
URN: 3254305 14
2.0 Materials and methods
2.1 Measurement of aluminium
2.1.1 Procedures to avoid contamination
Throughout sample preparation and testing a number of procedures to avoid 
contamination were undertaken. Reverse osmosis/de-ionised (RO/DI) water, obtained 
on site from an Elgar water system, was used as a diluent. All glassware, pipette tips 
and plasticware used were cleaned by acid washing in 10% hydrochloric acid (Fisher) 
for at least 4 hours. 10ml trace-element free plastic sample tubes (TEKLAB) were 
used for sample storage. Metal-free plastics were used; non-aged glassware and 
aluminium apparatus were not used. Sample tube tops were not touched. Fresh pipette 
tips were used. Pipette-dispensers were cleaned by flushing out the inside of the tip- 
and wiping the outside of the tip- with the substance contained within the vessels. 
Non- powdered nitrate gloves were used throughout the procedures. New atomic 
absorption spectrometer cuvettes underwent air burns before use. Regular cuvette 
changes and atomic absorption spectrometry head cleaning took place. Controls and 
standards used within testing allowed an additional method contamination monitoring 
during trace element detection.
2.1.2 Preparation of aluminium standard additions
0.1ml of stock aluminium nitrate “spectrosol” solution lOOOmg/L (BDH, Analar) was 
pippeted into an acid washed measuring flask and made up to 100ml with RO/DI 
water to give a 1000pg/1 dilute solution. A series of further dilutions were made to
URN: 3254305 15
give a series of 10ml aluminium standard solutions: 50|rg/l, lOOjag/l, 150|xg/l, 
200(ig/l, 250|ig/l, 500jiig/l and 750jxg/L
2.1.3 Preparation of tissue samples
Approximately 0.5g of wistar rat liver microsomal tissue (Pete Kentish, university of 
Surrey) was placed in an acid-washed glass digestion tubes. 7ml of RO/DI water and 
2ml concentrated nitric acid (BDH, Analar) were pipetted into the tubes. The tubes 
were placed in a Techator digestion system (Perstop Analytical Ltd.). The controller 
was set to heat the tubes on a 15 minute ramp to 150 °C for 30 minutes. The tubes 
were removed from the block and allowed to cool before addition of 1 .0 ml of 
concentrated perchloric acid (BDH, Aristar). The samples were replaced in the 
heating block and reheated using in the steps of:
i) Temperature 150°C for 30 minutes, 15 minute ramp
ii) Temperature 200°C for 15 minutes, 15 minutes ramp
iii) Temperature 250°C for 15 minutes, lOminutes ramp
The samples were allowed to cool before proceeding to trace element analysis. All 
samples obtained via digestion were dissolved in 5ml 1% nitric acid (v/v) for the 
measurement of aluminium.
2.1.4 Trace Element Analysis
Samples were analysed for aluminium content using PYE Unicam SP9 Atomic 
Absorption Spectrometer and PU9000 furnace set to wavelength 309.3 nm and 
utilising an aluminium detecting hollow cathode lamp (See appendix 2 for full 
description of AAS set-up). Each sample was diluted with 1% HNO3 prior to the
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analysis- the final volume of each sample cup was 300pl, 450pl or ôOOpl. Peak 
heights were recorded.
2.2 Size exclusion Chromatography
2.2.1 Formation of the malic acid buffer
Two buffer solutions of malic acid were made up, one of pH 6.8, one of pH 5.0, each 
of concentration of lOOmM. 4.02g of Anhydrous L-Malic acid (Sigma) was weighed 
out and mixed thoroughly in a solution of 250ml of distilled water. The solution was 
made up to 300ml in volume with a concentration of 20% sodium hydroxide (Fisher) 
necessary to bring the solution to the required pH- 5.0 and 6.8.
2.2.2 Eluting a sample through an SEC column
The top cap was removed from the Econo-Pac 10 DG size exclusion chromatography 
column (BioRad, 732-2010) and the internal buffer was poured away to the 10ml 
level. 20ml of the appropriate pH malic acid buffer was added to the column. The 
bottom tip of the column was broken and the column was allowed to flow until the 
buffer had drained off to the level of the 10ml bed layer. 2.0ml of sample was added 
to the column by touching the pipette tip to the side of the column just above the bead 
layer and slowly loading the sample in a circular motion just above the bed level. The 
sample was allowed to run into the gel. 2.0ml of effluent was allowed to drain off. 
5.0ml of buffer was added, again in a circular motion, and 5.0ml fractions were 
subsequently collected in fresh sample cups. The fractions were analysed by atomic 
absorption spectroscopy (see 2.1.4).
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3.0 Results
The GFAAS results from each experimental section are presented in chronological 
order and the rationale behind the experiments referred to in the text. Each 
experimental section was performed in ‘sets’. The set identities were as follows:
Set 1- Microsomal tissue with aluminium spikes added before digestion, diluted 1:9 
Set 2- Microsomal tissue with aluminium spikes added before digestion, diluted 1:3 
Set 3- Microsomal tissue with aluminium spikes added before and after digestion, 
diluted 1:3
Set 4- Microsomal tissue with aluminium spikes added after digestion, diluted 1:3 
Set 5- Aluminium spikes in KC1 and sucrose, diluted 1:1 
Set 6 - Aluminium standards, diluted 1:3
Set 7- SEC fractions from a 0.1 mM AICI3 in HC1 acidified water (pH 4.5)
Set 8 - SEC fractions of 0.74 mM AlClg/OAmM Tfh in malic acid buffer (pH 6 .8 ), 
diluted 1:24
Set 9- SEC fractions of 0.74 mM AlClg/OAmM Tfh in malic acid buffer (pH 5.0), 
diluted 1:24
Set 10- SEC fractions of 0.1 mM AICI3 in HC1 acidified water (pH 4.5), diluted 1:24
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3.1 Method validation: GFAAS measurement of A1
In order to determine the parameters for the instrumentation (void volume, limit of 
detection) and to determine a basis for the later experiments (standard addition, 
standard curve, interference) method validation procedures were undertaken. Due to 
unexpected results from GFAAS aluminium measurement method validation 
consumed a large proportion of the project time allocation.
3.1.1 Limit of detection and quantification
For the limit of detection calculation 12 samples (Ir.o. -12r.o) containing only the 
reagents and diluents (with neither microsomes or aluminium) underwent digestion 
and testing:
Table 3.2: Table to show peak heights from a set of reagent only samples. All samples 
were tested twice.
Sample
No.
1 2 3 4 5 6* 7 8 9 10 11* 12"
Peak
height
26,
25
17,
18
18,
17
24,
18
17,
18
507,
823
30,
27
20,
18
22,
21
22,
20
135,
27
23
Measurements 507, 823, 135 were regarded as aberrations.
** Sample number 12, test 2/2 finished before completion.
Sample 6 of the set showed strong indications of contamination. Sample 11 gave a 
result which was obviously out of line with the other results (peak height=135). 
Sample 12 gave one blank reading where the GFAAS missed a cup. These results
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were considered aberrations. These results verified the expected peak height for 
reagent only samples to be low (Peak height 17-30) and no greater than that of a 
diluent only sample. This confirmed that set 1 and 2 reagent only samples had been 
contaminated (table 3.1). Using these results as a reference, high readings for 
subsequent reagent only samples provided a positive indication of contamination. 
Sample 1 was repeat tested twenty times and the standard deviation of this run was 
the basis of the limit of detection calculation. The twenty repeat readings gave peak 
heights ranging from 18 to 39 with a mean of 22.5 and a standard deviation of 4.52. 
10 times the standard deviation is equivalent to 45.2 and reading from a typical 
TEQAS graph the limit of quantification can be calculated (see figure 3.0). The limit 
of detection was extrapolated backwards from this number.
.'. Limit of quantification = O.Spg/l 
.". Limit of detection = 0.24pg/l
3.1.2 TEQAS controls
The TEQAS controls were serum samples containing known concentrations of 
aluminium: concentrations consistent and guaranteed by TEQAS. Concentrations of 
553, 559, 693, 677 and 678 after 1:3 dilution were 11.9pg/l, 5.2pg/l, 36.1pg/l, 12.33 
pg/1, 10.0pg/l. TEQAS aluminium-serum standards numbers: 533, 539, 693 or P, 677 
and 678 underwent trace element analysis at the start of each days GFAAS testing. 
150pl of each control was added to 300jj1 1% nitric acid diluent (a 1:3 dilution). A 
standard curve was constructed from the results of 553, 539 and 639/P; and checked 
against 677 and 678. A typical graph is given below:
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Figure 3.0: TEQAS derived standard curve for aluminium content in serum. Chart to show 
concentration and peak height for 3 TEQAS controls 559, 553 and 693. Al concentrations of 
559, 553 and 693 w ere of 5.2, 11.9 and 36.1 microgrammes per litre. Samples w ere diluted
1:3.
TEQAS controls were used in clinical serum Al measurement as standards- to 
calibrate standard curves for serum samples. In this project we were not testing serum 
and made up and used our own standards additions. However the TEQAS controls 
were retained in this experiment and provided another, external source of control. 
TEQAS control peak heights were expected to vary between batches and days due to 
variation reflecting intermediate imprecision (see section 3.1.6). The slope of the 
curves obtained remained approximately the same however The graph was considered 
accurate if the Al concentration of 677 and 678 was calculated to within 1 s.d. of the 
known concentrations (677 = ±2.61, 678 = ±2.43).
3.1.3 Standard additions
Aluminium standard additions (see 2.1.2) were added to test cups to give a final 
concentration of between 5pg/l and 70pg/l. Later standards additions included higher
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concentrations (up to 185pg/l) to compensate for a dampening interference effect. The 
standard additions were designed to cover the range of aluminium concentrations 
likely to be found in later experiments. Variations in the final Al concentration of the 
test cups occurred due to variability in other factors: such as the dilution factor, final 
cup volume and addition of two aluminium spikes- one before and one after digestion. 
The series of standards were tested independently to provide a reference for later 
experiments and monitor for unexpected results. Figure 3.1 shows the peak heights 
obtained from the GFAAS measurement of aluminium in the series of standards 
additions. As expected the graph obtained displays the change in aluminium content 
of each sample well.
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Concentration of Al3+spike in test solution (m icrogramm es/litre)
45 60 65 70
Figure 3.1: Chart to show  concentration against peak hieght for the 
standard  additions in diluent (Set 6). Samples w e re  diluted 1:3. 
Samples w e re  m easured tw ice at each  concentration (n=2). +/- 1s.d. 
are show n. The final Al spike concentrations w ere : 16.7, 33.3, 50, 
66.7 microgrammes/l.
♦  standards
Linear (standards)
R-squared = 0.977
The regression equation for set 6 is: y  = 7.36x + 67.8
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Each increase in peak height is in proportion to the increase in aluminium content, 
that is linearity is shown. Statistical correlation is strong. This graph closely matches 
that obtained form analysis of TEQAS controls (see figure 3.0).
3.1.4 Measurement of Al in liver microsomal matrix
Male wistar rat, liver microsomal suspension (25%) (Pete Kentish, university of 
Surrey) was used in these tests. Sets consisted of 12 samples containing microsomes, 
microsomes and aluminium standard additions or reagents only. All samples with 
microsomes contained equal amounts of microsomes (1.75ml). Reagents present 
were those from the digestion process (see 2.1.3). Reagent only samples provided 
reference values but were not included in graphical or statistical processes as they 
were not part of the series of Al standards and contained no microsomes. Standard 
additions were added before digestion in the early sets and before and after digestion 
in the later sets. Later GFAAS runs tested single samples from sets with a range of 
standards added. The diluent used was 1% nitric acid. The usual dilution factor for 
samples containing liver microsome matrix was 1:3.
3.1.4.1 Microsomal samples with Al spikes added before digestion 
Male wistar rat, liver microsomal suspension (25%) (Pete Kentish, university of 
Surrey), was divided into a 9 samples of a 12 sample set and aluminium spikes added 
before the digestion. Three repeat sets were digested and tested.
In set 1 (samples 1-12) the three samples containing the highest spikes contained 25% 
less microsomes (1.5ml) than the other microsome containing samples (which held 
2ml). After digestion samples followed the trace element analysis procedure 2.1.4. Set 
1 was diluted 1:9 (sample: diluent). In set 2 samples were diluted 1:3. In set 2 all
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microsomal samples contained equal amounts of microsomes (1.75ml). In all other 
respects the composition of set 2 samples were identical to set 1. Set 3 samples used 
1:3 dilution. Set 3, Run 2 contained a sample with both repeat readings high and 
exceptional. This sample was considered contaminated and not included in the 
graphical representation or statistical analysis. The GFAAS skipped a sample cup in 
set 3 run 2.
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Figure 3.2: Chart to show concentration and peak height for two repetitions 
of samples 4-12. Samples were diluted 1:9. At zero concentration the 
samples contained microsomes only. At higher concentrations the samples 
contained microsomes, reagents and an Al standard addition of 7.33 or 
24.7 microgrammes/l.
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Figure 3.3: Chart to show concentration and peak height for set 2 (samples 4b-12b). Samples were diluted 
1:3. At 0 concentration samples contained microsomes only. At concentrations 22.2 and 74 
microgrammes/l samples contained microsomes and an Al standard addition. Standards were added before 
digestion.
♦  run 1
□  run 2
----------- Linear (run 1 )
 — Linear (run 2)
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Figure 3.4: Chart to show concentration and peak height for two repetitions 
of set 3 (samples 4c-12c). Samples were diluted 1:3. Samples contained 
microsomes only (concentration 0) or microsomes and Al standard addition 
of 22.2 or 74 microgrammes/l added before digestion. Results suspected of 
contamination were not included. GFAAS skipped cup in run 2.
♦  run 1
□  run 2
----------- Linear (run 1)
-----------Linear (run 2)
Set 1, 2 and 3 did not show the well correlated positive linear trends expected. The 
slopes are negative or only weakly positive (m<0.8). The data correlation in all cases 
is very weak (R-squared <0.3) though this may be partly due to the limited number of 
spike concentrations used (2). The data highlighted a number of important issues: 
contamination, interference, variation, possible flaws in the SOP and possible 
instrumental defects, as well as human error. These factors all had the potential to 
affect results. Measures were taken to minimise, control or quantify each.
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3.1.4.2 Microsomal samples with Al spikes added before and after digestion 
Two samples from set 3, which were representative of the means within each 
subgroup, were selected and a series of standard additions added. Run 1 used a sample 
containing microsomes alone (5c), run 2 used a sample with microsomes and 
aluminium spike (9c). In order to decrease the effect of variation on the correlation 
and linear regression, the number of spikes added was increased. This was achieved 
by adding standards after digestion as well as before. The time of the spike addition 
itself made no difference to the experimental results, but by adding spikes after 
digestion the addition was easier and allowed flexibility. Samples were diluted 1:3.
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Figure 3.5: Chart to show concentration and peak height for two samples 
from set 3 with standards added. +/-1 s.d are shown. Run1 used sample 5c 
with microsomes and Al spikes added after digestion diluted 1:3. Run2 used 
sample 9c with microsomes and spike before and after digestion diluted 1:6. 
Final standard concentrations were 8.3, 16.7, 25, 33.3, 58.3,100, 141.7 & 
183.3.concentration. n=3 for run 1(5c). n=2 for run 2. (9c).
R-squared Run 1 = 0.198, R-squared Run 2 = 0.784
Regression equations for the two samples of set 3 are- Run \ : y  = -0.184x + 82.6
Run 2: y = 0.55Ix + 54.7
♦  sample 5c
■  sample 9c
---------- Linear (sample 9c)
---------- Linear (sample 5c)
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The first sample run of set 3 (see figure 3.5) relative to the first three sets gave a 
negative trendline and poor correlation. No obvious signs of contamination or 
instrumental error were present in run 1 of set 3. The small concentration range over 
which the aluminium spikes were used may have been a factor in explaining the 
unclear results. Set 1 run 1 (figure 3.2), which also used a limited concentration range, 
gave a similar regression equation (negative trendline) and poor correlation.
The second run of set 3 (figure 3.5) monitored Al spikes at higher levels and through 
a greater range. In contrast to run 1, run 2 showed a positive trend and was relatively 
well correlated (R-squared=0.784). Positive and well correlated trendlines were 
expected, however comparison with the standards (figure 3.1) shows the trendline and 
correlation poorer than that expected.
3.1.4.3 Microsomal samples with Al spikes added after digestion 
Male wistar rat liver microsomal suspension 25% (g/v) (Pete Kentish, university of 
Surrey) was divided into 9 samples of a 12 sample set (set 4). No standard additions 
were added before the digestion. The set underwent digestion as described in 2.1.3 
and trace element analysis as described in 2.1.4. Two microsomal samples 
representative of the mean absorbance (the samples obviously contaminated were 
disregarded) were selected and a series of standards added to each. Samples were 
diluted 1:3 before testing.
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Figure 3.6: Chart to show concentration and peak height for three samples from set 4 
each with a series of standards added. +/-1 s.d are shown. Runl used sample 4d, and 
spikes of 5.55,11.1,16.7, 22.2, 27.8, 55.5. Run2 used 5d and spikes of4.17, 8.33, 16.7, 
25, 33.3 66.7. Run 3 used sample 6d and spikes of 25, 33.3, 41.7, 83.3, 125. All 
samples consisted of microsomes with Al spikes added after digestion. Samples 4d and 
6d were measured twice at each concentration (n=2). Sample 5d was measured three 
times at each concentration (n=3). Samples were diluted 1:3.
♦  sample 4d
□  sample 5d
A sample 6d
----------- Linear (sample 4d)
-----------Linear (sample 5d)
 Linear (sample 6d)
R-squared Run 1 = 0.961, R-squared Run 2 = 0.0654, R-squared Run 3 = 0.98 
Regression equations from samples from of set 4- Run l : y  = 0.613x + 35.0
Run 2:y = 0.484x + 52.3 
Run 3:y = 0.254 x + 56.6
The correlation between peak height and concentration seen in set 4 runs 1 and 3 
(samples 4d and 6d) was strong (R-squared>0.92). The trend slope was slight and 
positive (m=0.26-0.6 Ij, corresponding to many of the trends of previous results.
These results were considered good representations of the effect of liver microsomal 
matrix interference effect on the measurement of aluminium. Run 2 (sample 5d), 
which did not show good correlation, was considered a poor result and not 
representative of the matrix interference. It was decided that further experiments using 
liver microsomes would not be undertaken.
William Riddington 29
URN: 3254305
3.1.4.4 Interference in the microsome samples
The liver microsome matrix was having an interference effect of some kind. By 
comparing the first three sets (figure 3.2, 3.3 & 3.4) to the standard additions (figure
3.1) a major dampening effect was clear. To make sure the aluminium concentrations 
remained detectable, after the first set the dilutions used were lowered from 1:9 to 1:3.
3.1.4.5 Variation in the microsome samples
Secondly significant variation was occurring. The trendlines and regression equations 
between sets and runs differed- sometimes emphatically (see figure 3.2 & 3.5). To 
quantify inter- and intrasample variation and give a measure of levels of imprecision 
occurring, an ANOVA test was prepared for the controls of each set (section 3.1.6). In 
addition the limit of detection was calculated (see 3.1.1). The limit of detection gave 
the concentration level where inaccuracy and imprecision could be expected due to 
poor detection resolution. As the l.o.d. was low (pg/1) variation from instrumentation 
‘noise’ can be largely disregarded as a major source of variation.
Problems with instrumentation and contamination became increasingly apparent 
through the microsome testing and were a likely source of variation. The GFAAS 
occasionally skipped cups (see figure 3.4). Occasional results within the two repeat 
readings of a single sample were highly inconsistent with each other. Although 
proscribed by statistical methodology but in keeping with the standard NHS SAS 
practice, results which were obviously inconsistent with their repetition partner were 
discarded or repeated- typically those results outside 1 0 0 % of their repeat reading (see
appendix 3). One high or exceptional peak height from two repeats was considered an
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aberration or due to instrumentation (high intrasample variation). Two high repeat 
readings were considered to be an indication of sample contamination.
3.1.4.6 Contamination in the microsome samples
Contamination was implicated in the data from some of the results and probably a 
cause for some of the variation seen. Very high peak heights (over 150) which were 
obviously out of line with a prevailing trend were suspected of contamination (such as 
seen in figures 3.2, 3.3, 3.4, 3.6 and 3.7. An indication of contamination could be seen 
in some of the reagent only samples from the initial sets.
Table 3.2: Table to show the mean peak heights of the reagent only samples. All 
samples were tested twice (n=2 ).
Sample
Identity
Set 1 Run 1 
Peak height
Set 1 Run 2 
Peak height
Set 2 
Peak height
Set 3 
Peak height
Reagent only 737.5 772.5 502 25.5
Reagent only 461.5 754.5 313 17.5
Reagent only 255 289.5 224 17.5
Reagent only samples were expected to contain very little aluminium and have peak 
heights equivalent to blanks or diluent. Therefore the readings from set 1 and 2 were a 
strong sign that contamination had occurred in these and possibly other samples of 
those sets (figures 3.2 & 3.3). Either the reagents or the diluent were the logical 
source of contamination. Highly contaminated samples were strongly suspected o f  
carrying over to the next samples in a run, though this effect was only clear in those
samples not affected by interference (controls and diluents). Contamination of the
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samples containing microsomes may have been less evident due to the interference 
effect. High peak height was most apparent at the start of the sets and became less 
apparent as the set progressed. This indicated that the likely sources of contamination 
were the pipette tips of the reagent bottles. Extra measures and greater care were 
taken during the preparation and testing to avoid contamination (2.1.1). New diluent 
was prepared. All differences between the SAS SOP and our SOP were minimised. 
Reagent only samples were tested to establish the baseline aluminium levels expected 
in the reagents.
As the experiment progressed these interference, contamination, variation and unclear 
results indicated the need for additional sets to be prepared and tested and were the 
rationale for repetition of microsome experiments (sections 3.1.4.2 & 3.1.4.3). 
Isolation and quantification of the sources of problems, minimisation of 
contamination and human error and the acquisition of a good representation of the 
true interference effect became the objectives of this part of the project.
3.1.5 Measurement of aluminium in KC1 and sucrose
It was decided to extend the study of the testing for interference to two components 
necessary for tissue suspension in tissue fractionation- KC1 and sucrose. Sucrose was 
a component of the tested microsomal solution. Both of these substances would be 
necessary components of liver homogenate suspensions in future studies using this 
tissue. A 0.1M KC1 solution and a 0.25M solution of sucrose were run through 
digestion and trace element analysis as described in 2.1.3 and 2.1.4. Aluminium 
spikes were added before and after digestion. It was necessary to repeat set 5 GFAAS
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testing, as the first results were lost due to the autosampler being out of line with the
cuvette.
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Figure 3.7: Chart to show concentration and peak height for a KCI sample 
and sucrose sample. Run1 used 0.1M KCI sample with Al spikes added 
before and afer digestion. Run2 used 0.25M sucrose sample with spike 
added before and after digestion. Final standard concentrations were 7.5, 25, 
32.5, 50 16.7, 25, 32,5, 57.5, 100, 107.5. Samples were diluted 1:1.
♦  KCI 
■  sucrose
----------- Linear (sucrose)
-----------Linear (KCI)
The results from both the KCI and sucrose were poorly correlated (R-squared <0.650) 
the KCI particularly so. The trendlines were dissimilar KCI negative and sucrose 
positive and the baseline values (concentration^) for each differed considerably- 
though the low R-squared values mean any trend is not significantly apparent. 
However as neither samples displayed obvious proportional increase in peak height 
with Al concentration, both samples indicated the occurrence of the extensive matrix 
interference seen with microsomes (3.1.4). A high variation was seen in the KCI 
sample results- perhaps a result of contamination or another effect.
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3.1.6 Variation within the TEQAS controls
Testing of TEQAS controls occurred concurrently with most sets (see section 3.1.2).
Table 3.3: Table to show the different peak heights for the control samples.
Run
1
Run
2
Run
3
Run
4
Run
5/6
Run
8/9
Run
1 0
Run
1 1
Run
13
Run
14
Run
15
559 rpt 1 61 NR 89 74 78 NR 65 74 83 77 57
559 rpt 2 51 NR 80 71 78 NR 73 73 138 81 61
553 rpt 1 127 130 140 132 107 107 128 2 0 1 163 130 140
553 rpt 2 123 141 135 126 1 1 0 179 155 190 174 138 156
677 rpt 1 1 2 2 133 144 141 118 161 157 116 165 150 91
677 rpt 1 125 137 148 170 1 2 0 135 156 1 2 2 162 140 113
678 rpt 1 91 104 130 133 98 1 1 2 141 125 2 2 1 115 91
678 rpt 2 1 0 2 109 133 133 98 118 144 1 2 1 130 NR 79
NR = No Results
ANOVA was performed on the data. This method allowed us to obtain a measure of 
the variation within control groups and the variation between the groups. Midway 
through testing control P was replaced by control 693. The ANOVA was carried out 
on samples 553, 559, 677 and 678 only.
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Table 3.4: Table to show the sum of squares results of one-way ANOVA performed 
on each control group.
Sum of squares 
between groups
Sum of squares 
within groups
Sum of squares 
total
Degrees of 
freedom
559 4063 1656 5719 17
553 10615 3341 13596 2 1
677 7493 1096 8589 2 1
678 12752 4320 17072 2 0
Only the sum of squares results of the ANOVA were of relevance. The sum of 
squares values showed that variation within the TEQAS controls was mainly between 
groups and not within. This indicated the major source of variation was between 
batches and days rather than within batches.
3.1.7 Calibration curve for GFAAS measurement of aluminium in liver microsomal 
matrix
The results from the standard series (3.1.3) and the two most representative result sets 
from the previous liver microsomal matrix experiments (section 3.1.4) allowed us to 
construct a calibration graph for the interference effect of liver microsomal matrix.
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Figure 3.8: Calibration chart for Al m easurem ent in liver microsome: 
series of the standard additions and se t 4, run 3 and 4 are plotted. +/-1 
s.d are shown. Number of sam ples at each concentration w as 2.
Sam ples were diluted 1:3.
Regression equation for a: y  = 0.613x + 35.0 
Regression equation for b: y  = 0.254 x + 56.6
standards 
set4 runl 
set4  run3 
Linear (standards) 
Linear (set4 runl) 
Linearjset4jrun3)
Comparison of the trends shows the extent of the dampening effect of liver 
microsomal matrix on aluminium matrix. These results indicate that the interference 
effect would prevent sufficient sensitivity in aluminium detection for the intended 
experiments involving this type of matrix.
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3.2 Size exclusion chromatography
Due to project time allocation running out at this point analysis of the % yields of 
aluminium obtained from the SEC elutions could not be carried out.
3.2.1 Method validation: determination of Vo and Vi
Quarter of a spatula of dextran blue (Sigma) was made into a 2.0ml solution with 
lOOmM malic acid buffer pH6 .8 . A quarter of a spatula of bromophenol blue (BDH) 
was made into a 2.0ml solution with lOOmM malic acid buffer pH 6 .8 . Each sample 
was run through an SEC column as described in 2.2.2 except the column effluent was 
subsequently collected in 1 0 ml measuring cylinders until the dye had been fully 
eluted. A careful note was taken of the volume at which the dye first appeared and 
stopped appearing in the effluent.
Table 3.5: Table to show the volumes of effluent at which dye colour of dextran blue 
and bromophenol blue no longer apparent. The initial effluent volume- equivalent to 
the sample volume- was not included as part of any fraction.
Sample Volume in which dye first 
apparent
Volume at which dye no longer 
apparent
Dextran Blue 1 ml 4.4ml
Bromophenol Blue 8.5ml 31.0ml
The total volume within each SEC column can be expressed as: Vt = Vo + Vi + V g .
Where Vt is the total volume, Vo is the void volume, Vi is the volume within the
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beads and Vg is the volume taken up by the beads- Vg is negligible and can be 
discounted from the equation.
The void volume calculated from the data was 1.0ml to 4.4ml (3.4ml). Only high 
molecular weight molecules could be expected to be eluted in this volume.
A dissipated blue colour was apparent in the effluent within the void volume. 
However this was not considered representative of the deep, opaque, purple-blue dye 
which was first apparent at 8.5ml and last apparent at 33.0ml. The elution volume Ve 
of bromophenol blue was 8.5ml to 31ml. Before initiating the SEC Al-Tfn pH 
dependence binding experiments it was necessary to assess the interference caused by 
the malic acid buffer and obtain calibration graphs if interference was present. The 
next stage of the method validation was the measurement of aluminium in fractions 
eluted from a test sample.
3.2.2 Method validation: SEC test sample
A test sample composed of 37pM Al (lmg/1) in a pH 6 . 8  malic acid buffer was run 
through an SEC column as described in 2.2.2. A series of standard additions was 
added to samples from each fraction. These samples were tested for aluminium 
concentration as described in 2.1.4 using a 1:6 dilution.
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Figure 3.9: Chart to show concentration and peak height for a 
series of SEC fractions each with Al spikes added. Fraction 1 = 0- 
5ml efluent. Fraction 2 = 5-10ml. Fraction 3 = 10-15ml. Fraction 4 
= 15-20ml. Fraction 5 = 20-25ml and fraction 6 = 25-30ml. 
Samples were diluted 1:6. Final concentrations of the added 
spikes were 8.33, 16.7, 25 microgrammes/l. Samples were diluted
♦ fraction 1 □ fraction 2
A fraction 3 X fraction 4
« fraction 5 O fraction 6
"Linear (fraction 1) "Linear (fraction 2)
Linear (fraction 3) Linear (fraction 4)
" Linear (fractionJ5) Linear (fraction 6)
Table 3.5: R-squared values and regression equations for the SEC fractions plus 
standards of Al-test sample.
Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 Fraction 6
R-Squared 0.784 0.805 0.987 0.991 0.951 0.466
Regression
Equation
_y=9.44x+404 y=4.45x+792 y=T0.8x+380 y=9.42x+381 y=9.97x+377 y=13.4x+42
High peak heights were recorded. It was apparent from the results that the malic acid 
buffer did not cause interference comparable to that seen with liver homogenate, and 
KCI and sucrose. The regression equations of each fraction were similar, with the 
exception of fraction 2. Fraction 6 contained a high result suspected of contamination, 
which when removed from the analysis brings the regression equation and correlation 
in line with the other fractions 1-4. Fraction 5 contained an obviously contaminated
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pair of results, which was not included in the graphical representation or the 
regression analysis. The slope of fraction 2 was a little under half that of fractions 1-4.
The results showed that aluminium was present in high concentrations in fraction 2. It 
was not expected that fraction 2  would contain the highest concentration of 
aluminium. Free Al3+ ions having a low molecular weight were expected to be present 
in fractions 4 through to fraction 6 . Due to time allocation it was decided there were 
not enough resources to pursue this further method validation (by investigation of the 
possible causes for high concentration exclusively in fraction 2 ) but to continue with 
the pH binding experiments. The alternative and accurate means of monitoring 
interference by checking the aluminium yield from the samples was not performed for 
the same reason. The 10mg/l level of aluminium was chosen, as it would result in 
detectable levels of aluminium if the aluminium were to be distributed over a number 
of fractions at maximum concentration and with 1: 6  dilutions. Due to the high peak 
heights measured in fraction 1 where little or no aluminium was expected it was 
decided to test the malic acid buffers for Al concentration.
3.2.3 Analysis of the malic acid buffer aluminium content 
The malic acid buffers pH 6 . 8  and pH5.0 were analysed for aluminium content (as 
described in 2.1.4). 1:3 dilution was used. The aluminium contents of each buffer 
solution were calculated by the use of a standard curve derived from TEQAS controls 
(section 3.1.2). The buffers were found to contain very high levels of aluminium (80- 
110pg/1). The level of aluminium in the pH5.0 buffer was lower at 82pg/l than the 
higher pH buffer (pH6 .8 ). The high levels of aluminium were probably inherent in the
malic acid. Some of this may have been due to storage of the buffer in non-acid
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washed glassware. An increase in the concentration of Al in the SEC sample was 
implemented to ensure peak heights were detectable in the fractions over the 
background Al in the buffer. The high concentration allowed for the possible spread 
of the Al in a sample over several fractions.
3.2.4 Determination of the pH dependence binding of Al-Tfn 
Two sample solutions of 0.4mM transferrin and 0.74mM A1J+ (20mg/l) in 2ml malic 
acid buffer were prepared: one sample was at pH 6.8 the other at pH 5.0. The samples 
were allowed to stand for 10 minutes for solution equilibration before being run 
through fresh columns as described in 2 .2.2- except that fraction 2 was collected as 
5x1 ml samples. The fractions were analysed by GFAAS as described in 2.1.4. Sample 
dilution was 1:24.
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Figure 3.10: Chart to show SEC fraction volume and peak height for sets 8 & 9,
11. Set 8 was a series of SEC fractions from a 0.74mM Al, 0.4mM Tfn sample in 
pH 6.8 malic acid buffer.+/-1 s.d are shown.Set 9 was the series of SEC fractions 
from a 0.74mM Al, 0.4mM Tfn sample in pH 5.0 buffer (n=2). Samples were 
measured twice at each concentration. Samples were diluted 1:24.
♦  Al-Tfn pH 6.8
□  Al-Tfn pH 5.0
2 pei. Mov. Avg. (Al-Tfn pH 6.8)
------------2 per. Mov. Avg. (Al-Tfn pH 5.0)
William Riddington
URN: 3254305
41
Figure 3.10 clearly shows two very similar elution profiles: indicating that the 
aluminium in both pH samples to have been eluted at almost identical volumes. Both 
sets of results showed the highest Al levels were detected in volumes 5-10ml, peaking 
at 7-9ml and with higher than average Al levels were also seen in fraction volume 10- 
15ml. The data does not clearly show the presence of aluminium in fractions other 
than fraction 2. Both results showed aluminium being eluted almost exclusively as a 
high molecular weight complex (within early fractions).
Low levels in later fractions may have not been discernable due to (a) the high peak 
heights involved possibly compromising sensitivity, (b) the high background levels of 
aluminium in the buffer. A final experiment to verify the elution volumes of free Al3+ 
ions through the Biorad columns was undertaken. To ensure the free Al3+ ions were 
present in the sample a simple low pH buffer and eluent of acidified water was 
chosen. In order to decrease the range of peak heights to levels typically expected 
from a serum Al analysis the dilution was kept at 1:24 but the sample molarity was 
decreased to O.lmM.
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3.2.5 Control sample of AICI3
A 0.1 mM sample of aluminium chloride (Sigma) was eluted through an SEC column 
as described in 2.2.2 except R/O/DI water, acidified to pH4.5 with a dilute solution of 
concentrated hydrochloric acid (Fisher), replaced malic acid as the sample diluent and 
SEC eluent. The fractions underwent trace element analysis as described in 2.1.4.
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Figure 3.11 : Chart to show SEC fraction volume and peak height for set 10. Set *  AICI3 pH 4.5 
10 was the series of SEC fractions from a 0.1 mM AICI3 sample in pH 4.5 acidified 
water buffer. +/-1 s.d are shown. Samples were measured twice at each
concentration (n=2). Samples were diluted 1:24. 2 per. Mov. Avg. (AICI3 pH 4.5)
The results show aluminium present in high concentrations in the SEC volumes 15- 
35ml, with peak amount amounts present in fraction volumes 20-30ml. These results 
suggest that aluminium is present as a low Mw complex: as free ions. Ve of 
bromophenol blue started earlier but ended amount the same volume. This is 
consistent with aluminium being a lower Mw particle than bromophenol blue.
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4.0 Discussion
4.1 Interpretation of Results
4.1.1 Interference
From the outset of the experiments an interference effect was apparent (see figure
3.2). An extensive dampening of peak heights expected from spiked samples was 
reproduced in all experiments involving liver microsomal matrix. The initial results 
showed significant differences between trendlines and the data was poorly correlated 
(see figures 3.2, 3.3 & 3.4). These differences could have been interpreted as a 
fluctuation in the interference effect or even as possible evidence of curvature of the 
trendline. It therefore became important to obtain an accurate representation of the 
interference effect and show linearity. Satisfactory evidence of linearity (an R-squared 
correlation of 0.95 or above) was not shown in the initial results (see figures 3.2, 3.3 
& 3.4). Improvements in experimental procedure produced an increasing quality of 
correlation and consistency of trends. Contamination decreased. There was an 
increase in number of spikes added and range of concentrations used. Good data 
correlation seen in figure 3.6 gave evidence of linearity between 0-56pg/l and 0- 
125pg/l. No clear link existed between experimental improvements and data quality 
however it can be said that: linearity was not proved when using lower concentration 
ranges or with a lower number o f  spikes. It is likely that the difficulties encountered 
obtaining a reliable data correlation and consistency were due to a combination of 
contamination, variation in results, and the shallow slope produced by the interference 
effect.
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Interference and matrix effects are reported in past papers (Taylor & Walker, 1992). 
The interference may have occurred in two ways. Firstly the loss of aluminium from 
the microsomal samples may have occurred by the formation of volatile species of 
aluminium- such as AICI3 . This process would occur in the preparation phase. 
Secondly the formation of certain substances or aluminium species may reduce the 
atomisation efficiency during the trace element analysis. An example of this would be 
analyte trapping on condensed matrix particles (Freeh, 1996). Many substances exist 
within a complex matrix organic such as liver microsomes which could interfere with 
aluminium detection within GFAAS or cause volatisation; such as phosphates, Ca2+, 
Mg2+, Zn2+ and Fe2+ (Valkonen & Aitio, 1997). Previous experiments involving liver 
samples are did not show any problems or interference from such substances 
(Bouman et a l, 1986). Sample digestion and preparation are procedures designed deal 
with potential sources of interference and to break down organic molecules. The 
inclusion of reagents such as nitric acid is meant to prevent volatisation. The 
acidification of the sample ensures that the aluminium present remains in solution, 
preventing adsorption effects and the formation of salts (ICPS EHS, 1994). Past 
research has not reported significant interference problems with biological tissues as 
long as adequate preparation procedures are performed (ATSDR, Bouman et a l,
1986; Lopez et a l, 2000; aLopez et a l, 2002; bLopez et a l, 2002). The most likely 
source of the interference encountered would be a component of the matrix solution. 
Both KC1 and sucrose are simple matrices. Sucrose phosphate was present as a 
component of the liver microsomal matrix. KC1 and sucrose are necessary for isotonic 
cell solution formation (and would have been used in the experiments originally 
intended to follow this one). Interference was also indicated when KC1 and sucrose
solutions were tested (figure 3.7). The results were not clear however. Data from the
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KC1 samples were particularly poorly correlated perhaps an indication of 
contamination or another effect, such as AICI3 formation. It is plausible that KC1 
could have an interference effect by formation of the volatile species AICI3 . The 
presence of nitric acid should have prevented this from happening. It is possible that 
after digestion when little or no nitric acid remained in a sample, but before 
reconstitution with nitric acid, that KC1 and aluminium reacted to form volatile AICI3 - 
which would have been subsequently lost before measurement (Taylor, A. pers. 
comm.). This is unlikely however. Past papers do not make any mention of serious 
interference in biological or liver samples some of which will have used KC1 in the 
solution. The digestion and preparation procedure used in this experiment are similar 
or identical to established, commonly used technique for biological tissues.
Sucrose is a simple organic molecule. Sucrose would be expected to be fully broken 
down by the reagents of the digestion process. Excessive levels of carbohydrates or 
fats can lead to interference (Sepe, 2001). Problems with digestion have been reported 
when high concentrations of sucrose have been present (>25%). The digestion in 
these cases produced black residue (Taylor, A pers comm). No residue was observed 
in the digestion products of the experimental samples. Papers detailing matrix effects 
typically report that the reduction of measurable aluminium does not exceed 1 0 % 
(Freeh, 1996). The interference effect encountered when testing liver microsomal 
matrix was excessive.
4.1.2 Contamination
Contamination was undoubtedly a factor when interpreting the results. The
contamination particularly apparent in the initial results involving liver microsomes
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(figure 3.2,3.3 & 3.4) made interpretation of these results difficult. Contamination 
occurred throughout the experiment. Sources of aluminium contamination extended 
further than obvious sources such as pipette tips or handling. Leaving samples open to 
the air and circulating dust was suspected to be have caused contamination. Storage 
conditions (such as pH, temperature and matrix) of serum and biological samples 
have been reported to affect measurable A1 levels (Wilhelm & Ohnesorge, 1990). The 
differences in the baseline concentrations of the malic acid buffers may have been due 
to the different pH (section 3.2.3). It is likely that the high levels of aluminium 
measured in the buffers were due to aluminium inherent in the malic acid reagent. 
Malate is a cheleator of similar character to citrate. Past papers stress the difficulties 
associated with contamination when attempting measuring aluminium (ATSDR,
1999). Depending on the level of accuracy required, measures should be taken to 
determine the aluminium content of reagents.
It should be remembered that the dampening effect of the interference may have 
reduced peak heights of some contaminated samples and hidden them from 
observation. Any samples so affected would have not been obvious but have 
contributed to variation in the data.
4.1.3 Data variation
The examination of the variation within the data and investigation into its sources 
constitute a major part of the method validation. Variation in the data was apparent 
and suspected to underlie the difficulty in obtaining a clear indication of the 
interference effect (figures 3.2, 3.3, 3.4, 3.7). Examination of the data and statistical
analysis was performed to identify the nature of the variation. The limit of detection
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and quantification calculation gave us a figure for variation due to instrumental noise. 
However this calculated limit of detection/quantification is theoretical. From the data 
as a whole it was obvious that a pg/ 1  level of sensitivity was not being reliably 
attained. Other experiments measuring aluminium in biological tissue set limits of 
detection around 0.2-2pg/l (ATSDR, 1999, Raggi et al., 2000, Volkonen & Aitio, 
1997). In practice the theoretical limit of detection is lower than that of the practical 
limit of detection (also referred to as functional sensitivity). We can speculate the 
functional sensitivity lies between the limit of detection and limit of quantification but 
further experiments using spiked samples would be needed to accurately evaluate this 
value. The limit of detection calculated did not signify that instrumental noise was 
high.
The ANOVA sum of squares values (see 3.1.6) values showed that the greater 
proportion of variation was coming from between the groups (on a ratio of 3:1 to 7:1). 
The between group scores corresponded to intermediate imprecision which included 
interbatch variation and interday variation. The lesser variation seen in the within 
groups value corresponded to variation from instrumentation. This confirmed the low 
instrumentation noise level signified in the limit of detection, reagent only samples. 
The imprecision levels of the control groups were (coefficients of variation) were 
24.1%, 18.1%, 14.7% and 24.2% for 559, 553, 677 and 678. The accuracy showed by 
the GFAAS was generally good shown by the tendency of measured values of 
aluminium for the controls to be within 1 standard deviation of the target value of the 
known value. Contamination of samples was the greatest source of inaccuracy. In 
addition it is probable that the greatest source of imprecision is also due to 
contamination (ATSDR, 1999; ICPS, 1997).
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4.1.4 Size exclusion chromatography
The results from the size exclusion chromatographic separation of aluminium- 
transferrin were not expected. A described in the results, the elution of aluminium 
from both pH Al-Tfn samples occurred almost completely with the 5-10ml SEC 
fraction. The aluminium was eluted in the earliest volume outside of the Vo 
suggesting complexion in a high molecular weight complex with a molecular weight 
of less than 6000Da.
Transferrin is well outside the exclusion limit (Mw 80,000Da) and will be completely 
eluted within the first fraction: within the Vo. On the other hand aluminium when 
dissociated from Tfn is expected to be present as a free ion or in a low molecular 
weight species (such as spéciation with malate, AI-C4 H6 O5). The molecular weights 
of both these are very low (27Da and 134 Da respectively) and these molecular 
weights will be eluted in the highest volume fractions. The expected peaks within 
fraction 1 and around fractions 4-7 did not occur. This would indicate that in these 
samples aluminium was neither bound to transferrin or present as a free/low 
molecular weight complex. This is contradicted by the similar early elution from the 
preliminary test sample. The almost identical elution profiles o f both aluminium 
transferrin samples and the similar early elution seen in the preliminary test sample 
would suggest that the presence o f  transferrin did not make a difference to elution o f  
aluminium in these conditions. The logical extension to this indication would be that 
transferrin does not form a complex with aluminium in these conditions. This clearly 
contradicts confirmed research. These results must be considered an aberration.
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A possible explanation for these results could be a disassociation from transferrin as it 
moves through the column. A1 exchange between sample and column packing has 
been commonly reported (Harris, 1999). The early elution may have simply been 
aluminium from within the column. However the column used had properties which 
should have prevented exchange from occurring. Another explanation is the 
interference of the buffer eluent or column packing material with the critical 
bicarbonate ion within transferrin, though this also was not predicted in the column 
used.
The common factor in the 3 samples affected by early elution (preliminary and two 
Al-Tfh samples) is the malic acid buffer. The final SEC sample of AICI3 in acidified 
water buffer the early elution effect was not present and aluminium was detected in 
the high volumes as a low molecular weight complex. It is possible to speculate that 
the malic acid is causing the early elution effect, such as through Al-malic acid 
complexes clumping together into high Mw complexes. However this would be 
speculation. No satisfactory interpretation of these SEC results can be made. Further 
work into this phenomenon would be necessary. Past papers do not report similar 
early elution using SEC as a technique for separating aluminium in simple, inorganic 
matrices and organic matrices (Busch & Seubert, 1999; Platen & Lund, 1997; 
Koether, 2002).
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4.2 Further experiments
This preliminary study brought into question the methods more than it validates them. 
Further studies inquiring into the source and nature of the interference effect and the 
SEC early elution effect were indicated as well as studies to pursue the original 
objectives of the project. Further studies which may logically proceed as a result of 
this preliminary study can be categorised:
(a) Repetitions of the same method validation and techniques, using newer 
instruments and different sets of reagents
(b) Modifications and improvements of the existing procedures
(c) Completely new techniques
The unexpected and seemingly unexplainable results are in themselves a cause for 
scientific enquiry. The experimental techniques used in this project are based on well 
tried and scientifically established procedures. It is logical to surmise that the results 
from the experiment are erroneous rather than that of the accumulated data from all 
previous experiments involving these techniques. It is hoped that repetition of the 
method validation with newer instrumentation and different reagents may trace the 
cause of the interference to something as banal as instrumentation or inadequate 
sample preparation. The SEC early elution effect is not quite as simple to study. 
Though repetition is also recommended, inquiries into other aspects of the experiment 
are also indicated. Primarily these would be investigation of the performance of 
alternative buffers to malic acid for the SEC and an investigation into the possibilities 
of interactions between the reagents, samples and the column used. For a thorough
inquiry as to the sources of the main difficulties (interference and early elution, each
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aspects of the method validation each needs to be isolated and tested and analysed for 
performance. However the nature of such experiments are clinical and analytical, not 
biological. Improvements and modifications to the existing protocol that are directed 
towards experiments with the objectives of studying intracellular Al-Tfh behaviour 
are possible. Extraction of the aluminium from the biological matrix with a solvent 
such as EDTA should produce a reduction of matrix interference and increase the 
sensitivity of the subsequent GFAAS aluminium measurement. Extraction with a 
solvent and subsequent measurement using GFAAS is also and established technique 
(ATSDR, 1999; LeGendre & Alfrey, 1976). Alternative digestion techniques exist. 
Addition of the matrix modifying agent Triton X-100 in the sample preparation 
should also reduce matrix effects (Valkonen & Aitio, 1997). Stabilised platforms in 
atomic absorption spectrometers and end-caps on cuvettes have been shown to reduce 
matrix effects (Freeh, 1997; Valkonen & Aitio, 1997). However when considering the 
extent of the interference effect from this experiment, improvements in techniques 
leading to only minor reductions in the matrix effect have little merit. Contamination 
would remain a potential problem. The more complicated the sample preparation and 
the greater the number of reagents the increase in the risk from contamination.
Alternative methods could be used to measure aluminium in biological samples. ICP- 
AES and ICP-MS are possible alternatives though the limit of detection of ICP-AES 
is unfavourable compared to GFAAS. ICP-MS has an increased sensitivity and 
sample preparation follows a different course. However ICP-MS needs skilled 
technicians and is an expensive technique (ATSDR, 1999; ICPS, 1997). Alternatives 
exist for the separation of transferrin and free or low molecular weight aluminium
species. Ultrafiltration is the most viable alternative, recommended by previous work
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though anion exchange HPLC is another alternative (Harris, 1999, Sanz-Medel et al., 
2002).
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4.3 Conclusions
On the basis of the results shown by this experiment method validation would be an 
essential component of subsequent experiments. Essential to the method validation 
would be a calibration curve. Interference effects would need to be within an 
acceptable level, much lower than that obtained in this project. Stringent procedures 
to avoid contamination would likewise be considered essential. On the basis of the 
interference effect shown in this experiment being reproduced the sample preparation 
and GFAAS techniques utilised cannot be recommended for aluminium measurement 
in liver microsomal matrices. It should be noted that results from an individual 
GFAAS machine may be dissimilar from other GFAAS instrumentation.
The results from the experiments in this project have been eccentric and difficult to 
explain. Few insights can be made concerning pH dependence binding of aluminium 
transferrin. The objectives of successful method validation and determining the pH 
dependence binding al aluminium to transferrin were not achieved. It is proposed that 
lack of technical proficiency with instrumentation, and the instrumentation and study 
design are factors in- or may underlie- the overall failure to attain the objectives.
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Aims & Objectives:
The aim of this project is to increase our understanding of how aluminium moves 
from blood to cells in the brain. High levels of aluminium administered intravenously 
have been shown to cause dialysis dementia, a progressive neurodegenerative disease- 
the incidence of which has almost disappeared due to filtering of dialysate water. The 
accumulation of aluminium in the brain is often associated with Alzheimer’s disease 
but the role aluminium plays in the pathogenesis is uncertain. To enter the brain 
aluminium must be taken up by endothelial cells, pass across these cells and be 
released into the interstitial fluid of the brain to be taken up by neurones and glial 
cells. The objectives o f the study are to provide information, which can be used to 
elucidate details of these mechanisms. In particular we will determine:
1. Whether the pH dependence of the binding of aluminium to apotransferrin and 
aluminium transferrin to their receptors is the same as the iron transferrin 
system.
2. The intracellular movement of aluminium. The movement of aluminium 
transferrin and aluminium between the various compartments of the 
endosomal system of hepatocytes.
3. If these initial stages are successful and prove the viability of the experimental 
techniques and premises; then the subsequent aim will be to examine the 
uptake of aluminium-transferrin by cultured endothelial cells, astrocytes and 
neurones and whether and in what form it is released from cells.
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Background:
2.1 Aluminium exposure & toxicity:
Aluminium is a very abundant metal on the earth’s surface. Typically a human being 
is exposed to 2mg-100mg of Al3+ per day [4], with averages of 6mg/day-60mg/day
[7]. Lifestyle, diet and geography are factors that account for large differences in 
exposure levels. The common sources of Al3+ are food, water, cooking utensils, 
medicines and antiperspirants (principally food) Industrial pollution is an increasing 
source of exposure. Acid rain has led to high levels of Al3+ in drinking water in some 
regions of Scandinavia [6,7].
Table 1: Sources o f A13+ in man
Common sources o f  A l for man. Al concentration in the source, resultant daily A l exposure from the source, estimated bioavailability from 
the source and calculated amount o f  Al absorbed daily.____________________________________________________________________
Estimated percentage Daily Al absorbed
Source A l concentration Daily Al exposure absorbed (pg/kg)a
Norma! exposure
0.3bWater Average — 70 pg/1 100 pg 0.005
Food 5000-10.000 pgc 0.1-0 .3d 0.08-0.5
Air-rural 0.2 pg/m3 4 pg 1.5-2 from lungs? 0.001
0.1-0 .3  from GI tract 0.0001
Air-urban 1 pg/m3 20 pg 1.5-2 from lungs? 0.006
0.1-0.3 from GI tract 0.0006
Antiperspirants 5-7.5%r 50.000-75.000 p c up to 0.012e up to 0.1
Vaccines 150-S50 pg/dose 1.4-S pg" 100 eventually' 0.07-0.4
Elevated exposure
SOAntacids/phosphate up  to 5.000.000 pg 0.1
Binders
Industrial air 25-2500 pg/m3 250-25.000 pg per work 1.5-2 from lungs® 0.6-8
day 0.1-0.3 from GI tract 0.008-1
Allergy immunotherapy 150-850 pg/dose 7-40  pg* 100 eventually1 0.1-0.6
Dialysis solution If tap water 50 pg/1 2400 pg 25k 9
Total parenteral Neonatal/infant 11-27 pg/kg 100 11-27
nutrition solutions 110-270 pg/11
Adult 40-135 pg/11 80-270 pg 100 1.2-1.2
u Based on a 65 kg adult except for vaccines (20 kg child) and total parenteral nutrition solution in neonates and infants. 
b From table 3.
c Bennington & Schoen (1995).
d Estimates based on daily urinary Al excretion/daily A l intake from food and Stauber cl al. (1999).
* Based on Al exposure in an industrial setting: Gilelman et a l  (1995): Pierre el al. (1995).
r Based on 20% Al zirconium glycine complex or 25% Al chlorohydrate in a topical product, which are typical concentrations (PO ISINDEX  
information system. Micromedex. Inc. Englewood. CO. USA). 
e Based on Flarend et al. (2001). assuming that the percentage o f  A l absorbed does not change with repealed exposure. 
ü Based on 20 injections in the first 6 years o f  file and an average weight o f  20 kg.
1 Flarend et al. ( 1997).
■I Based on a typical allergen extract treatment schedule and maintenance injections for 3.5 years o f  one allergen extract. 
k Kovalchik et al. (197S).
1 Based on maintenance fluids and normal neonatal/infant or adult electrolyte supplementation.
Source: Yokel & McNamara 2001.
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Oral absorption, the route of greatest exposure for most people is not the route that 
provides the greatest potential risk from systemic Al3+ accumulation and toxicity [1]. 
Al3+ is absorbed poorly from the gut. An estimated 0.3% of the aluminium exposed to 
the body in water drunk is absorbed. The absorption from inhaled pollution is higher 
at 1.5% - 2%. Dialysis patients may absorb up to 25% of aluminium present in water. 
Al3+ in intravenously applied vaccine has a bioavailability of 100%.
The spéciation of Al3+ affects uptake from the GI tract considerably. Absorption by 
the GI tract is affected by pH and the presence of complexing carboxylates [4]. Citrate 
increases bioavailability possibly due to increased solubility. Soluble forms of 
aluminium are absorbed from the gut much more efficiently than insoluble forms. 
However actual movement of Al3+ across the gut wall is not with citrate but with the 
transferrin molecule and receptor. The presence of hydroxide also increases 
absorption from the gut. Hydroxide and citrate together have a synergistic effect on 
Al3+ uptake. The presence of fluoride in drinking water decreases Al3+ bioavailability
[6 ]. The spéciation of Al3+ is believed to be relevant in explaining a lack of toxic 
effects with aluminium-antacid ingestion, the ingestion of which may increase 
exposure to gramme levels [6 ]. Variation in the bioavailaibility of aluminium in 
drinking waters may be due to variation in the spéciation of aluminium.
At high levels or with chronic intake aluminium has been shown to be associated with 
toxic effects in man. Primary sites for toxicity of aluminium are the central nervous 
system, skeletal system and haematopoietic system [1 ]; the principle toxicity is 
associated with CNS effects and neurodegeneration. The mechanism by which
aluminium contributes to CNS damage is not understood, conflicting evidence exists
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as to its role in neurodegeneration and disorders such as Alzheimer’s disease. It has 
been established that patients exposed to high levels of aluminium in dialysate fluids 
develop ‘dialysis neuropathy’ also known as ‘dialysis dementia’- a progressive fatal 
neurological syndrome first characterised by speech disorder and dementia. Post 
mortem examination of the brains of these patients showed aluminium-enriched 
fibrillar material- tangles. The subsequent introduction of measures to minimise the 
aluminium in dialysate fluids has prevented the occurrence of dialysis neuropathy.
The occurrence of encephalopathy has also been reported in patients with chronic 
renal failure after the ingestion o f Al3+ containing antacids [1].
Though aluminium can be seen to be associated with dialysis neuropathy, its role in 
the pathogenesis of other diseases is not clear. Aluminium can act as a potent 
neurotoxicant- in vitro administration of aluminium to cultures of neurones or glial 
cells results in accumulation and damage [2,3]. Increasing the concentration of Al3+ in 
the brains of sensitive mammalian species such as cats to 4pg/g from Ipg/g can 
induce impaired brain function and neurodegeneration [4]. The existence of species 
differences and acute toxicity studies failing to reproduce human exposure to 
aluminium limits the relevance of animal studies to mankind however. Aluminium 
has long been thought to be associated with Alzheimer’s disease (AD). Emphasising 
this putative link is the presence of aluminium in the neurofibrillary tangles and senile 
plaques of many AD patients. These plaques are not the same as the tangles of 
dialysis dementia and it may be that accumulation of aluminium is secondary to 
nervous system damage. The administration of the Al3+-chelator desferrioxamine has 
been shown to delay onset of AD and statistically positive correlations between
aluminium in drinking water and Alzheimer’s indicate a connection [5,6]. On the
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other hand an absence of increased incidence of AD in dialysis patients and the lack 
of correlation between the use of aluminium containing antacids and AD are major 
arguments against a direct causal role of Al3+ in Alzheimer’s. Epidemiological, 
human- and animal studies indicate it is probable that aluminium, though a potent 
neurotoxicant acts as a co-factor rather than a direct causative agent in 
neurodegenerative disorders such as Alzheimer’s [1,5,6].
The evidence that direct (intravenous or intrathecal) administration of aluminium 
causes neurotoxicity is offset by the lack of clear correlation between human exposure 
to aluminium and neurotoxicity. This can be explained in part by the movement of 
aluminium across cellular barriers in the body. Thus significant levels of aluminium 
in the serum either from direct administration or from very high doses can be 
expected to cause toxicity. This raises the issue of the movement of Al3+ from the 
serum across the blood brain barrier and into neuronal cells. Aluminium shows a 
biodistribution, which is marked by accumulation in the brain and bone. The normal 
human body burden of A1 is between 30mg and 50mg [4]. The bone and lung have the 
majority of the body burden. The brain has around one percent- approximately Ipg/g 
- 2pg/g. The distribution and storage of Al3+ occurs in more than one compartment. 
The bone and particularly the brain have long elimination t°5. An aluminium 
elimination t0 ' 5 from the human brain of several years is predicted from rat and 
radioisotope studies. The low turnover of brain cells in adults helps account for a very 
long predicted half-life. This is compounded by gradual redistribution out of the bone.
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2.2 Aluminium movement in the body:
The uptake and movement of all trivalent ions in the body is severely restricted. 
Trivalent ions do not enter cells by pumps or channels (active or facilitated diffusion)
[8 ]. However iron is a required element the uptake and movement of Fe3+ is specially 
facilitated by the transferrin molecule (Tfh) and transferrin receptor (TfiiR). Iron 
unlike aluminium may exist in a divalent as well as trivalent state (Fe2+ and Fe3+). It 
is because of the potential of iron as an oxidising agent (Fe3+ -»  Fe2+) that it is kept 
controlled within the body and bound to transport molecules. Iron in its divalent ion 
state (Fe24) can be taken up by the divalent metal ion transporter (DMT1).
Initially the distribution of Al3+ is consistent with blood volume and 85% - 90% of 
aluminium in serum is complexed with the transferrin molecule [4,9]. The remainder 
of the serum aluminium is bound to mainly to citrate, but also hydroxide and 
phosphate molecules, with some amino acid binding. These charged complexes do not 
diffuse across membranes. However Al-citrate is readily distributed into tissues and 
likewise Al-transferrin is also readily distributed into tissues.
Table 2: Major Al-binding ligands within the body.
The predominant binding ligands for At in r/ro. their effective equilibrium constants with A l. their concentrations in plasma and brain 
extracellular fluid (based on values in cerebrospinal fluid), and the percentage o f  A l predicted to be associated with that ligand (all data  
provided by Wes Harris)._______________________________________________________________________________________________ _ _ _ _ _ _ _ _ _
Ligand
n flèc the equilibrium  
constant with Al 
(log)
Plasma Brain extracellular fluid
Concentration
(pmol/l)
% o f  A l
species
Concentration
(pmol/l) % o f  AI sp x ies
Transferrin 13.7. 12.6 30 91 <0 .25 4
Citrate 11.6 99 7-S ISO 90
Hydroxide (free) 6.5 0.4 <  1 0.4 5
Phosphate 9.3 1100 <  1 490 1
Source: Yokel & McNamara
It is apparent that transferrin and citrate are the two predominant aluminium-ligand
complexes within the body. Citrate, also known as citric acid, is a simple 6 -carbon
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containing tricarboxylic acid. Citrate is an endogenous molecule present in all cells 
and tissues of the body [10]. Aluminium forms a low molecular weight complex with 
citrate. Aluminium distribution and excretion is enhanced by citrate [4,11]. 
Transferrin is a molecule, which transports ferric ions between sites of utilisation, 
storage and uptake. Transferrin is able to cross cell membranes and body 
compartments. The total serum concentration of transferrin is around 35pM, with an 
iron binding capacity of double that figure. Fe3+ ions bind more strongly than Al3+ to 
transferrin. In normal conditions only a third of the serum binding capacity of 
transferrin is utilised by ferric ions. The remaining binding capacity of transferrin of 
up to 50pM is enough to preclude competition by aluminium. The highest serum 
aluminium ion levels now seen in dialysis patients, is up to 5pM.
2.3 Transferrin & the Transferrin receptor:
Transferrin is a single polypeptide chain of 80,000 Da weight and a composition of 
679 amino acids. Transferrin has a carbohydrate element (<6 %) of 2 N-linked glycan 
chains. The transferrin molecule assumes a bilobular conformation; furthermore each 
lobule contains 2 domains. An iron-binding cleft exists between the two domains of 
each lobe [12]. The lobes, domains and clefts of transferrin are not identical; the two 
lobes share a 40% sequence homology [13].
The two iron binding sites of transferrin have a high affinity for the Fe3+ ion. In both 
sites the ferric ion is bound in a six-coordinate binding environment. Two tyrosine, 
one histidine and one aspartic acid amino acid residues provide 4 ligand-binding 
groups. A bicarbonate ion provides the fifth and sixth coordination sites. The
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bicarbonate ion is essential in the binding of Fe3+ to transferrin. No metal-protein 
binding occurs in the absence of this bicarbonate ion, known as the synergistic anion. 
On the binding of iron to transferrin the two domains rotate towards each other by 
approximately 60 degrees giving a closed conformation. This structural change is 
important in regulation and receptor binding.
Figure 1: Transferrin
X \ V \  ! X
Ferric N -I-obc C om plex
Source: Harris, W. (2002)
N  L obe A pop so iem
Transferrin shows high affinity binding, in vivo, to a number of other trivalent metal 
ions including Al3+. Al-Tfn does show differences from Fe-Tfn binding such as a 
preference for the N-lobe of Tfh and a lower affinity [11,14]. The movement of 
transferrin and ligand into cells is facilitated by the transferrin receptor. The 
transferrin receptor consists of 2 identical polypeptide subunits each of molecular 
weight 95,000 Da. Two subtypes TfnRl and TfnR2 exist. TfnRl is present on the 
plasma membrane of all human cells and most abundant in rapidly proliferating cells. 
TfnRl is subject to downregulation by levels of the intracellular iron binding 
molecule ferritin. Hepatocytes and cells lining the blood brain barrier display large
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amounts of TfnR2, which is not subject to downregulation [11]. The Tfh receptor has 
a high affinity for diferric transferrin, medium affinity for monoferric transferrin and 
low affinity for apotransferrin.
Fig 2: Transferrin Receptor
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2.4 Transferrin receptor mediated endocytosis (Tfn-ME):
Transferrin bound transferrin receptors are taken into cells by receptor mediated 
endocytosis. Plasma membrane with bound receptor is taken into the cell by 
invagination of the membrane. Clathrin molecules coat the forming vesicle and aid in 
providing a shape. The clathrin molecules are shed from the vesicle as it moves into 
the cell. Endocytosed vesicles merge with internal vesicles known as early 
endosomes. Early endosomes are the location for sorting and targeting. Subsequent
William Riddington 73
URN: 3254305
endosomes may bud off the early endosome for further intracellular movement. 
Endosomes can be divided into distinct populations, with different destinations and 
activities [10]. Endosomal- and vesicular movement is mediated by microtubules.
Late endosomes are involved in sorting and are located in geographically distinct 
areas of the cell. Late endosomes are sited towards the perinuclear (centre) of the cell. 
The contents of late endosomes tend to be destined for lysosomes or the Golgi 
apparatus. Endosomes may also be cycled to another surface of the cell in 
transcytosis.
Receptor endosomes are recycled back to the cell surface from the early endosome. 
TfhR endosomes follow a recycling pathway, involving receptor endosomes. The 
recycling pathway allows TfhR to be moved back to the plasma membrane.
Early, receptor and late endosomes can be described as different compartments. Early 
and receptor endosomes can be distinguished experimentally: physically 
(centrifugation), biochemically (protein composition) and pharmacologically 
(differential sensitivity to AIF4 ) [15]. Protein composition of the endosomes is 
important in differentiation.
Figure 3: Simplified sequence of events in TfhR-ME
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Certain receptor endosomes such as those containing epidermal growth factor (EGF) 
are routed to lysosomes and degraded. Tfh receptors recycle from early endosomes, 
they do not become targeted to lysosomes, but significant amounts of Tfii receptors do 
recycle from late endosomes [15,16]. In certain cells such as hepatocytes and 
epithelial cells, experiments indicate some Tfh receptor undergoes transcytosis and is 
recycled to another cell face.
The membranes of endosomes contain ET ATPase pumps, which pump in H* from the 
cytosol. Low endosomal pH is an important factor in regulation and function.
Receptor endosome pH tends to be lower than early endosome pH. In receptor 
endosomes low pH (<5.0) induces a conformational change in transferrin leading to 
the release of Fe3 +ions. The low pH of recycling endosome alone is not enough to 
ensure conformational change in transferrin. The transferrin receptor aids the change
from di- or monoferric transferrin to apotransferrin [17]. Reductases within the
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endosome are believed to convert Fe3+ to Fe2+. A transmembrane divalent cation 
carrier (DMT1), believed to be specific for divalent ferric ions, is associated the 
release of Fe2+ ions into the cytosol from the endosome [18,19]. It is believed that 
Nramp2 is the divalent cation transporter DMT1, which facilitates the release of iron 
from Tfh endosomes [17]. Nramp2 (Natural Resistance Associated Macrophage 
Protein) is a phosphoglycoprotein of molecular mass around 100,000 Da possessing 
the characteristics of membrane transport proteins, such as a hollow helical structure. 
Nramp2 proteins are present in the plasma membrane and in recycling endosomes but 
are not functional at neutral pH [18]. Nramp2 is ubiquitous in cells and is colocalised 
with Tfh endosomes- supporting its proposed iron-transporting function.
It is probable that aluminium is released from transferrin in the same pH dependent 
manner as iron. As aluminium has no equivalent divalent ion to the ferric ion, it is 
highly improbable the Fe2+ release mechanism (DMT1) is utilised by Al3+. Indeed 
though it is known that aluminium gains access to cells by transferrin the extent to 
which Al3+ follows the course of Fe3+/Fe2+ is not known. Dissociation of both Al-Tfii 
from the Tfh receptor and Al3+ from Tfh, the possible release of Al3+ from the 
endosomal system and stage it occurs and the endocytotic pathway Al-Tfh takes are 
details which are yet unknown and are likely to be of relevance to understanding Al3+ 
entry to the CNS.
2.5 Mechanisms of aluminium transport into the brain:
The blood-brain barrier is a single layer of cells that is formed at the brain capillary 
endothelium and the choroid plexus epithelium. Tight junctions link the cells of the
BBB, providing a barrier against non-lipophilic agents in the bloodstream. Though
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endothelial cells possess transferrin receptors differences in the processing of Fe- 
transferrin by endothelial cells and other cells are thought to exist. In vitro studies 
using cultured endothelial cells show a rapid uptake of Fe-Tfh but with time both Tfh 
and aluminium were lost from cells whereas in hepatocytes the Tfh is expelled but the 
Fe3+ is retained and accumulates [20]. Though it is possible lysosomal processing and 
degradation of the iron may occur further studies have indicated the probability of 
transcytosis of Fe3+, the movement from the apical to the basolateral surfaces of the 
endothelial cell [21,22]. As cells within the brain require iron, it is probable that 
transcytosis of Fe-Tfh across endothelial cells followed by uptake into the interstitial 
fluid of the brain and uptake into glial cells and neurones.
It is not known if aluminium entry into the brain follows this course, it is known that 
iron homeostasis is altered by high doses of aluminium and that aluminium entry is 
mediated in part by TfhR-ME. The homeostasis of Al3+ in the brain is dependent on 
its transport into- and out of the brain, and its uptake by neurones and glial cells. 
Radiolabelled aluminium doses, using Al2 6  ions, demonstrates that TfhR-ME alone is 
not enough to account for the rate of aluminium entry into the brain. There is thought 
to be another mechanism, which facilitates the movement of aluminium across the 
blood brain barrier. The other major serum species of aluminium, Al-citrate, is 
believed be involved either in the Tfh pathway or by a separate process. Current 
research indicates Al-citrate can be transported across endothelial cell surfaces by an 
uncharacterised monocarboxylate transporter isoform expressed in the brain such as 
MCT7 or MCT8  or one of the several members of the organic anion transporting 
protein family [20]. Aluminium uptake into glial and neural cells may also involve
these transporter molecules. The aim of the study is to elucidate these processes.
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Figure 4: Proposed mechanisms by which aluminium enters, and is incorporated into the brain.
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Methods:
The absence of a suitable radioisotope is a fundamental problem in the study of 
aluminium toxicity. The radioisotope Al2 6  has been used successfully in many 
experiments but measurement of this substance requires the use of accelerator mass 
spectrometry, which is not available in the United Kingdom. A basis for the 
experimental design has been ensuring that the aluminium in the test materials is 
within a level, which can be detected by the equipment we intend to use. For this 
reason we have chosen to concentrate on the liver, in which cell fractionation 
procedures are well defined and where it is relatively easy to separate epithelial and 
endothelial cells. An assay of aluminium will be done in cell culture and tissue 
samples by atomic absorption spectroscopy. Using these methods the limit of 
quantitation will be 30pg.
1. The pH dependence binding of aluminium to transferrin will be carried out 
using commercially available short G15 or G25 sephadex gel columns (size 
exclusion chromatography). It should be noted that if  required a greater 
separation resolution could be achieved using that other gel columns such as 
TSK-HW55S [21].
2. Homogenisation of the liver causes hepatocytes to break into large sheets 
derived principally from the basolateral membrane and vesicles derived 
largely from the sinusoidal surface. The former may be obtained free from 
contamination but the latter contain the highest concentration of transferrin
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receptors. An assay of the binding of transferrin to transferrin-receptor will be 
performed using smooth surfaced liver microsomes prepared by sucrose 
density gradient centrifugation. Any remaining ribosomes will be removed by 
treatment with EDTA followed by pelleting. lodination of transferrin will be 
by standard procedures. Vesicle bound transferrin and aluminium will be 
determined either by centrifugation or ultrafiltration.
3. To investigate the movement of the aluminium-transferrin complex through 
the endocytic pathway an intravenous injection of preformed aluminium- 
transferrin complexes will be given to the rats and after 1,2 and 3 hours the 
livers will be extracted and homogenised. The concentration of aluminium in 
the liver homogenate, in the major fractions separated by differential pelleting 
and the microsomes re-fractioned on gradients of materials such as Percoll and 
metrizamide determined. Method development of this last step is likely to be 
needed to minimise the interference of the density gradient solute in the assay 
of aluminium.
4. The previous stages should indicate whether aluminium transferrin complexes 
remain in the endosome compartment or enter the cytosol either due to release 
of the aluminium from the endosome compartment or as a result of digestion 
in the lysosomes. The next putative step would be to examine whether the 
aluminium and transferrin are returned to the cell surface when freshly 
isolated hepatocytes and preparations enriched in endothelial cells, pre-loaded 
with aluminium-transferrin, are incubated in a fresh medium.
With the exception of commercially available transferrin the greatest costs of the
initial stages of the experiment is that of the time of skilled technical staff. The
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homogenised rat liver is pre-prepared and avoids the necessity of animal procedures. 
The commercially available transferrin price ranges from £250-350 per gramme 
depending on the formulation and amount, we will allocate approximately £200.
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Appendix II: Set up details for PYE Unicam GFAAS
The spectrometer was checked for readiness and set up as shown:
Phase Temp (°C) Time (Sec) Ramp Commands
1 dry 110 40 6
2 dry 140 10 7
3 ash 700 15 4
4 ash 1350 5 7
5 atomise 2800 3 0 TC, PT, AZ
6 clean 2900 3 0
Background correction- Off Sample volume- lOpl 
Precision- On Peak area- Off
Max.Lamp Current- 10mA Lamp current- 10mA
Resample no.- 2 
Bandpass- 0.5mm
Atomic N o .-13 Wavelength- 309.3nm Uncoated tube
William Riddington
URN: 3254305
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